CRISPR Therapeutics AG
CRSPNASDAQHealthcare● Active
$51.66
$-0.19(-0.36%)
Market Cap$5.0B
P/E Ratio—
52W High$78.48
52W Low$37.02
CRISPR Therapeutics AG (CRSP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CRSP · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.51M | $35.00M | $370.00M | $0.44M | $913.08M |
| Cost of Revenue | $232.96M | $110.25M | $130.25M | $110.25M | $101.18M |
| Gross Profit | ($229.45M) | ($75.25M) | $239.75M | ($109.81M) | $811.90M |
| Gross Margin %(computed) | — | -215.00% | 64.80% | — | 88.92% |
| Operating Expenses | |||||
| R&D Expenses | $265.33M | $320.65M | $387.33M | $461.64M | $340.57M |
| G&A Expenses | $73.54M | $72.98M | $76.16M | $102.46M | $99.69M |
| Total Operating Expenses | $338.87M | $391.32M | $462.29M | $563.35M | $438.38M |
| Operating Income | ($568.32M) | ($466.57M) | ($222.54M) | ($673.16M) | $373.53M |
| Operating Margin %(computed) | — | — | -60.15% | — | 40.91% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($577.97M) | ($362.67M) | ($150.72M) | ($650.50M) | $379.53M |
| Income Tax Expense | $3.63M | $3.59M | $2.89M | ($0.33M) | $1.87M |
| Net Income | ($581.60M) | ($366.25M) | ($153.61M) | ($650.17M) | $377.66M |
| Net Margin %(computed) | — | — | -41.52% | — | 41.36% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 |
| Wtd Avg Shares | 89.93M | 84.36M | 79.22M | 77.75M | 75.95M |
| EBITDA | ($548.84M) | ($447.31M) | ($202.70M) | ($648.99M) | $391.48M |
| EBITDA Margin %(computed) | — | — | -54.78% | — | 42.87% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more CRISPR Therapeutics AG data
About CRISPR Therapeutics AG (CRSP) Income Statement
CRISPR Therapeutics AG (CRSP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CRSP reported revenue of $0.00B, gross profit of ($0.23B) (gross margin -6537.01%), and net income of ($0.58B) — a net profit margin of -16569.77%.
Frequently asked questions
CRSP · 4 questionsCRISPR Therapeutics AG (CRSP) reported revenue of $0.00B for 2025, down 90.0% year-over-year.
CRSP revenueCRSP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08